Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 18/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18976773 | 0.91 | AOC3 (0.65) | AOC3KCNH2 | |
| SCHEMBL18976732 | 0.89 | AOC3 (0.60) | AOC3KCNH2 | |
| SCHEMBL18976930 | 0.86 | AOC3 (0.61) | AOC3KCNH2 | |
| SCHEMBL18976816 | 0.85 | AOC3 (0.60) | AOC3KCNH2 | |
| SCHEMBL18977360 | 0.84 | AOC3 (0.67) | AOC3KCNH2 | |
| SCHEMBL22997045 | 0.82 | AOC3 (0.79) | AOC3KCNH2 | |
| SCHEMBL2602381 | 0.81 | AOC3 (0.69) | AOC3KCNH2 | |
| SCHEMBL16067950 | 0.81 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL25765254 | 0.79 | AOC3 (0.65) | AOC3KCNH2 | |
| SCHEMBL22997161 | 0.78 | AOC3 (0.78) | AOC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN, LLC (US) | 2020-05-14 | — | — | US | claimed |
| CN-111032029-A | Vascular adhesion protein-1 inhibitors for the prevention or treatment of migraine | 普罗克斯马根有限责任公司 | 2020-04-17 | — | — | CN | claimed |
| EP-3194388-B1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN LLC (US) | 2019-08-14 | — | — | EP | claimed |
| US-10065954-B2 | Substituted imidazo[4,5-c]pyridines as SSAO inhibitors | PROXIMAGEN LIMITED (GB) | 2018-09-04 | — | — | US | claimed |
| US-20170362218-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-12-21 | — | — | US | claimed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN, LLC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN, LLC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3194388-B1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN LLC (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3194388-B1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN LLC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10065954-B2 | Substituted imidazo[4,5-c]pyridines as SSAO inhibitors | PROXIMAGEN LIMITED (GB) | 2018-09-04 | — | — | US | disclosed |
| US-20170362218-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-12-21 | — | — | US | disclosed |
| US-20170362218-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-12-21 | — | — | US | disclosed |
| US-20170362218-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-12-21 | — | — | US | disclosed |
| WO-2017098236-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | AOC3 55/4885KCNH2 1764/4885 |
| US-20170362218-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | SSB, PNPO, SSBP1 | AOC3 24/4885KCNH2 2665/4885 |
| US-10065954-B2 | Substituted imidazo[4,5-c]pyridines as SSAO inhibitors | MAOA, AOC2, AOC3 | AOC3 3/4885KCNH2 1289/4885 |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, SMOX | AOC3 4/4885KCNH2 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.